Search

everythinglearnresearchcommunity

for

Search:↓

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The conversation is about hair loss treatments, specifically using dutasteride and oral minoxidil, and exploring additional vitamins and supplements like vitamin D, zinc, biotin, and omega-3 to support hair health. Users suggest getting a blood panel to identify deficiencies and emphasize the importance of protein and overall nutrition.

The user reported significant hair growth progress after 6 months using 5mg oral minoxidil, 0.1mg dutasteride, 1.1mg finasteride, and 1mg biotin. They experienced some hair shedding but no noticeable side effects, and they regret not starting the treatment earlier.

The conversation discusses using finasteride pills to create a topical solution for hair regrowth, with mixed results. Users suggest that buying ready-made topical finasteride or switching to oral treatments might be more effective and convenient.

Personal experience with Procyanidin B2 shows it's ineffective for hair loss. Viviscal Pro supplement tablets, containing Procyanidin B2, didn't help after 8 months of use.

A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.

Minoxidil, finasteride, and RU58841 are discussed as hair loss treatments. User skepticism is expressed about the effectiveness of these treatments.

A user received a prescription for Dutasteride 0.5 in Europe and asked about the brand. Replies confirmed the brand's quality and suggested using the cheapest gelatin capsule form.

The user reported slight improvement in hairline using 1% Clascoterone cream over three months but found it too costly to continue. They expressed interest in trying a 5% concentration if it becomes available at a reasonable price.

A user is starting topical finasteride and minoxidil 3 times a week for hair loss and is experiencing high anxiety about the treatment's effectiveness and potential side effects. They are also taking vitamin D3 daily and are concerned about the application method and possible shedding.

The conversation is about making topical finasteride using stemoxydine as a carrier. The user is considering buying Redken Cerafill Hair Re-Densifying Treatment (Stemoxydine) 90ml for this purpose.

A 23-year-old male with slight hair thinning is using ketoconazole shampoo, biotin, zinc, magnesium, D3/K2, and has just started topical finasteride (0.0125%). He plans to add minoxidil (4.5%) with 17α-estradiol and is seeking advice on the effectiveness and side effects of these treatments, as well as the use of a dermaroller.

Unused Minoxidil tablets should be disposed of at a pharmacy with take-back services or according to packaging instructions. It's not recommended to give them to others due to legal and safety concerns.

The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

Finasteride and Dutasteride are used for hair loss, with Dutasteride often in gel form for better bioavailability. Switching from Finasteride to Dutasteride is common, with some users combining treatments like Minoxidil for improved results.

Amplifica has not provided updates on SCUBE3 and AMP-303, raising concerns about their trial outcomes. Users also mention other treatments like Minoxidil, finasteride, RU58841, PP405, and ET-03.

The user experienced significant hair improvement after switching from topical to oral treatments, using finasteride, minoxidil, and biotin. They reported no major side effects, except for slightly thicker hair on their hands.

RU58841 was used by some for hair loss, but concerns about side effects like gynecomastia and safety were raised. Alternatives like finasteride, minoxidil, pyrilutamide, and alfatradiol were discussed, with some users reporting better experiences with these treatments.

A user's successful 6-month journey with Minoxidil, Finasteride and 0.05 Derma Rolling to regain their hairline, eyebrows, facial hair and overall youthful look. They also discussed the use of topical minoxidil for eyebrow thickening, as well as other skincare routines and healthy lifestyle habits.

A user noticed hair thinning and was prescribed spironolactone, which led to increased hair loss. They were advised to switch to finasteride.

OP is considering making a 5% topical Clascoterone (Breezula) for hair loss, as they use Minoxidil but can't use Finasteride due to side effects. They seek advice on creating the topical safely, possibly with help from a trained chemist.

The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

The user experienced significant hair regrowth using a topical treatment of Minoxidil and Finasteride, despite some brain fog as a side effect. They recommend starting treatment early and suggest topical options to minimize side effects compared to oral treatments.

A 28-year-old man shares his positive experience with a 3-in-1 oral pill containing finasteride, minoxidil, and vitamins for hair loss, noting decreased bald spot width and overall hair thickening after four months. He encourages others to start treatment, mentioning the mental benefits and minimal side effects, while discussing additional treatments like ketoconazole and microneedling.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.